Powered by

-CSL's Global Role in Battling COVID-19

Apr 05, 2021 - ENP Newswire

CSL and AstraZeneca have agreed for CSL to manufacture approximately 50 million doses of Vaccine AstraZeneca in Australia for supply to the country. First doses were rolled out in March 2021.

CSL Behring has launched a clinical trial into the use of CSL312 (garadacimab, Factor XIIa antagonist monoclonal antibody) to treat patients suffering from severe respiratory distress, a leading cause of death in patients with COVID-19 related pneumonia. A Phase 2 study to assess the safety and effica...